- Reference code :
- wf389
- Published date :
-
28 April 2001
- Expired date :
-
13 September 2028
AstraZeneca today inaugurates a new $100m manufacturing plant in China - one of the largest investments by a Western pharmaceuticals company in the People's Republic.
The plant, located in Wuxi New District, near Tai Hu Lake, 200 kms north west of Shanghai, covers a total area of 96,000 square metres. Its estimated annual production capacity from leading edge facilities will be 1.5bn tablets, 70m capsules, 2.5m bottles of oral solutions, 4m bottles of dose-aerosols/sprays and 6m vials of sterile products.
The plant employs 280 people. The company's top selling Losec treatment for stomach acid disorders, as well as Plendil for heart disease and asthma treatments are among the products from AstraZeneca range to be produced there.
Further enquires to:
Media RelationsSteve Brown +44 (0)20 7304 5033 Chris Major +44 (0)20 7304 5028 |
Investor RelationsMichael Olsson +44 (0)20 7304 5087 |
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 05:46 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
